コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 the placebo group (one CMV; one EBV-related posttransplant lymphoproliferative disorder).
2 imary mediastinal B-cell, and 1 CR of 3 with posttransplant lymphoproliferative disorder.
3 ft nephropathy or viral infection, including posttransplant lymphoproliferative disorder.
4 plant overall, skin, solid malignancies, and posttransplant lymphoproliferative disorder.
5 r virus (EBV)-associated disorders including posttransplant lymphoproliferative disorder.
6 cytochemistry findings are consistent with a posttransplant lymphoproliferative disorder.
7 nts, who also experience higher incidence of posttransplant lymphoproliferative disorder.
8 mphomas, including Burkitt lymphoma (BL) and posttransplant lymphoproliferative disorder.
9 anagement of serious EBV diseases, including posttransplant lymphoproliferative disorder.
10 with multiple human malignancies, including posttransplant lymphoproliferative disorder.
11 no evidence of cytomegalovirus infection or posttransplant lymphoproliferative disorder.
12 development of graft-versus-host disease or posttransplant lymphoproliferative disorder.
13 have a 45% rate of progression to late-onset posttransplant lymphoproliferative disorders.
14 pleen were also introduced to reduce risk of posttransplant lymphoproliferative disorders.
15 induced by human immunodeficiency virus, and posttransplant lymphoproliferative disorders.
16 decreased IRF-1 expression in cases of human posttransplant lymphoproliferative disorder, a malignant
17 is associated with B cell proliferation and posttransplant lymphoproliferative disorder after alloge
18 d four children in group II (7.8%) developed posttransplant lymphoproliferative disorder after conver
19 ectrum of EBV latent gene expression in most posttransplant lymphoproliferative disorders and from th
20 ession, and there was no association between posttransplant lymphoproliferative disorders and pretran
21 tt's lymphoma (BL), HIV-associated lymphoma, posttransplant lymphoproliferative disorder, and nasopha
22 ell, immunoblastic large B cell, follicular, posttransplant lymphoproliferative disorder, and periphe
23 Risk of transplant pancreatic insufficiency, posttransplant lymphoproliferative disorder, and postspl
24 notherapy, for example, renal impairment and posttransplant lymphoproliferative disorder, and the eff
29 rr virus- (EBV) related disorders, including posttransplant lymphoproliferative disorder, constitute
30 reased risk of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder (EBV-PTLD) i
31 .2% at 12 months, and 99.1% of patients were posttransplant lymphoproliferative disorder-free through
32 ipients were alive with no single example of posttransplant lymphoproliferative disorder, graft-versu
33 After the diagnosis of posttransplant lymphoproliferative disorder, immunosuppr
34 iferative disorder was 10%; the incidence of posttransplant lymphoproliferative disorder in the last
36 iver failure (n=2), chronic rejection (n=3), posttransplant lymphoproliferative disorder (n=1), graft
37 deaths occurred from de novo cancer (n=13), posttransplant lymphoproliferative disorder (n=5), age-r
39 rvival and improved QALYs, without increased posttransplant lymphoproliferative disorder or cytomegal
40 on of the monoclonal clone or development of posttransplant lymphoproliferative disorders or other ma
41 s C virus or hepatitis B virus, disseminated posttransplant lymphoproliferative disorder, or late rej
42 wo reported cases of cyclosporine-associated posttransplant lymphoproliferative disorders presenting
43 outcome of Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after
46 or to mortality, including two patients with posttransplant lymphoproliferative disorder (PTLD) and o
47 There were no new safety signals and no new posttransplant lymphoproliferative disorder (PTLD) cases
49 rus (EBV) and associated with development of posttransplant lymphoproliferative disorder (PTLD) follo
67 nosis of Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder (PTLD) is re
68 on of immunosuppressive regimens (ISRs) with posttransplant lymphoproliferative disorder (PTLD) may b
70 ncidence of early Epstein-Barr virus-related posttransplant lymphoproliferative disorder (PTLD) was 9
73 pressants has raised the question of whether posttransplant lymphoproliferative disorder (PTLD), a co
76 children; in addition, 10 children developed posttransplant lymphoproliferative disorder (PTLD), whic
90 ype of cancer with the highest incidence was posttransplant lymphoproliferative disorder (PTLD, 1.58%
91 se The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) tri
92 10 to 406), non-Hodgkin's lymphoma including posttransplant lymphoproliferative disorder (PTLD; SIR =
99 gic differences between patients who develop posttransplant lymphoproliferative disorders (PTLD) earl
100 y was not associated with increased risk for posttransplant lymphoproliferative disorders (PTLD) in l
103 oreticular malignancies, collectively called posttransplant lymphoproliferative disorders (PTLD), eve
104 children and is associated with the risk of posttransplant lymphoproliferative disorders (PTLD).
105 mals with prolonged graft survival developed posttransplant lymphoproliferative disorders (PTLD).
106 was plagued with high risk of rejection and posttransplant lymphoproliferative disorders (PTLD).
107 xamine the incidence of and risk factors for posttransplant lymphoproliferative disorders (PTLD).
108 tion (BMT) is linked to an increased risk of posttransplant lymphoproliferative disorders (PTLD); how
109 The genetic mechanisms that give rise to posttransplant lymphoproliferative disorders (PTLDs) are
112 of lymphomas, but knowledge of their role in posttransplant lymphoproliferative disorders (PTLDs) is
115 munosuppressive agents foster development of posttransplant lymphoproliferative disorders (PTLDs), th
116 expressed in the majority of EBV-associated posttransplant lymphoproliferative disorders (PTLDs).
117 is also a known factor in the development of posttransplant lymphoproliferative disorder (PTLPD) in a
118 inhibitors (tacrolimus or cyclosporine) and posttransplant lymphoproliferative disorders related to
124 cytomegalovirus disease was 13%, and that of posttransplant lymphoproliferative disorder was 10%; the
126 skin, solid posttransplant malignancies, and posttransplant lymphoproliferative disorder were 3.2 (1.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。